Overview
Apellis Pharmaceuticals, Inc., based in the United States, operates within the biopharmaceutical sector, primarily focusing on innovative therapeutic treatments for autoimmune and inflammatory diseases. The company has pioneered the use of complement C3 inhibition technology, introducing a robust pipeline of drug candidates aimed at addressing a wide range of debilitating diseases with significant unmet medical needs. A key product, Pegcetacoplan, targets conditions like paroxysmal nocturnal hemoglobinuria and has extended its applications into geographic atrophy, underscoring Apellis' strategic reach in both rare diseases and broader medical conditions. Apellis' commitment to expanding treatment possibilities across various diseases makes it a notable entity in the biopharmaceutical landscape, poised for potential growth and clinical advancements.
AI+ Ask Fintel’s AI assistant about Apellis Pharmaceuticals, Inc..
Thinking about good questions…
Basic Stats
The share price of Apellis Pharmaceuticals, Inc. as of September 5, 2025 is $28.13 / share. This is an increase of 2.03% from the prior week. The market cap (or net worth) of Apellis Pharmaceuticals, Inc. as of September 5, 2025 is $3,549.64 MM.
The Factor Analysis chart (below right) shows a view of Apellis Pharmaceuticals, Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 3,549.64 MM |
| EV | 3,633.64 MM |
| Shares Out. | 126.19 MM |
| Earnings Date | |
| EPS (TTM) | -1.81 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 0.41 |
| Short Shares Avail. | 4.80 MM |
| Short Interest | 20.27 MM |
| Short Float | 25.86 % |
| Days to Cover | 10.48 days |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | -28.40 % |
| Volatility (1 yr) | 0.56 |
| Beta | 0.61 |
| Sharpe Ratio (1 yr) | -0.58 |
| Sortino Ratio (1 yr) | -0.99 |
| PE Ratio | -15.56 |
| Price/Book | 22.71 |
| Price/TBV | 22.71 |
| Book/Market | 0.04 |
| EBIT/EV | -0.06 |
| EBIT(3yr avg)/EV | -0.11 |
| ROA | -0.25 |
| ROE | -0.86 |
| ROIC | -0.36 |
| CROIC | 0.02 |
| OCROIC | 0.01 |
| Implied Volatility | 45.88 % |
| Put/Call OI Ratio | 0.26 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Apellis Pharmaceuticals, Inc. is $38.53. The forecasts range from a low of $19.19 to a high of $63.00. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Apellis Pharmaceuticals, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2022-11-15 | JP Morgan | Overweight | Maintains | |
| 2022-11-10 | Jefferies | Buy | Hold | Downgrade |
| 2022-11-08 | Credit Suisse | Neutral | Maintains | |
| 2022-10-18 | Raymond James | Strong Buy | Maintains | |
| 2022-09-12 | Wedbush | Neutral | Maintains | |
| 2022-09-08 | Stifel | Buy | Maintains | |
| 2022-08-18 | Oppenheimer | Outperform | Maintains | |
| 2022-08-09 | Raymond James | Strong Buy | Maintains | |
| 2022-08-09 | Goldman Sachs | Buy | Maintains | |
| 2022-08-09 | Credit Suisse | Neutral | Maintains | |
| 2022-07-20 | Citigroup | Buy | Maintains | |
| 2022-07-19 | HC Wainwright & Co. | Buy | Initiate | |
| 2022-05-24 | Goldman Sachs | Buy | Maintains | |
| 2022-05-05 | Raymond James | Strong Buy | Maintains | |
| 2022-05-05 | Credit Suisse | Neutral | Maintains | |
| 2022-04-14 | Roth Capital | Neutral | Sell | Downgrade |
| 2022-04-04 | JP Morgan | Overweight | Maintains | |
| 2022-03-07 | Goldman Sachs | Buy | Maintains | |
| 2022-03-01 | Raymond James | Strong Buy | Maintains | |
| 2022-01-11 | Raymond James | Strong Buy | Maintains | |
| 2021-12-08 | Wells Fargo | Overweight | Initiate | |
| 2021-11-29 | Roth Capital | Buy | Neutral | Downgrade |
| 2021-11-24 | Citigroup | Buy | Maintains | |
| 2021-11-09 | Raymond James | Strong Buy | Maintains | |
| 2021-09-10 | Wedbush | Outperform | Neutral | Downgrade |
| 2021-09-10 | Roth Capital | Buy | Maintains | |
| 2021-09-10 | Needham | Buy | Maintains | |
| 2021-09-10 | Credit Suisse | Neutral | Maintains | |
| 2021-09-10 | BMO Capital | Outperform | Maintains | |
| 2021-08-19 | Wedbush | Neutral | Outperform | Upgrade |
| 2021-08-19 | Jefferies | Buy | Initiate | |
| 2021-08-10 | Raymond James | Strong Buy | Maintains | |
| 2021-08-10 | Credit Suisse | Neutral | Maintains | |
| 2021-07-08 | BMO Capital | Outperform | Maintains | |
| 2021-07-02 | JP Morgan | Overweight | Maintains | |
| 2021-06-28 | Needham | Buy | Maintains | |
| 2021-05-21 | UBS | Buy | Initiate | |
| 2021-04-29 | Credit Suisse | Neutral | Maintains | |
| 2021-04-16 | Goldman Sachs | Buy | Initiate | |
| 2021-02-26 | Credit Suisse | Neutral | Maintains | |
| 2021-01-29 | Credit Suisse | Neutral | Maintains | |
| 2021-01-08 | Raymond James | Strong Buy | Maintains | |
| 2020-12-15 | Roth Capital | Buy | Maintains | |
| 2020-11-23 | Citigroup | Buy | Maintains | |
| 2020-11-19 | Needham | Buy | Initiate | |
| 2020-09-01 | Stifel | Buy | Initiate | |
| 2020-07-20 | Roth Capital | Buy | Initiate | |
| 2020-06-30 | Citigroup | Buy | Maintains | |
| 2020-06-17 | BTIG | Neutral | Initiate | |
| 2020-06-08 | JP Morgan | Overweight | Maintains | |
| 2020-04-28 | Cantor Fitzgerald | Overweight | Maintains | |
| 2020-04-01 | Raymond James | Strong Buy | Initiate | |
| 2020-03-31 | BMO Capital | Outperform | Initiate | |
| 2020-03-11 | Wedbush | Underperform | Neutral | Upgrade |
| 2020-03-02 | Credit Suisse | Neutral | Maintains | |
| 2020-01-08 | Oppenheimer | Outperform | Maintains | |
| 2020-01-07 | Baird | Overweight | Maintains | |
| 2019-12-19 | Bank of America | Buy | Initiate | |
| 2019-11-25 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2019-11-22 | Wedbush | Underperform | Initiate | |
| 2019-11-05 | Credit Suisse | Neutral | Initiate | |
| 2019-07-12 | JP Morgan | Neutral | Overweight | Upgrade |
| 2019-07-09 | Oppenheimer | Outperform | Initiate | |
| 2019-03-29 | Baird | Outperform | Initiate | |
| 2019-01-23 | JP Morgan | Overweight | Neutral | Downgrade |
| 2018-11-14 | JP Morgan | Overweight | Overweight | Maintains |
| 2018-09-13 | B. Riley FBR | Buy | Buy | Maintains |
| 2018-08-08 | Cantor Fitzgerald | Overweight | Overweight | Maintains |
| 2018-07-30 | B. Riley FBR | Neutral | Buy | Upgrade |
| 2018-07-10 | Cowen & Co. | Outperform | Initiate | |
| 2018-05-24 | Cantor Fitzgerald | Overweight | Initiate | |
| 2018-04-12 | B. Riley FBR | Buy | Neutral | Downgrade |
| 2018-04-12 | B. Riley | Buy | Neutral | Downgrade |
| 2018-03-23 | JP Morgan | Overweight | Overweight | Maintains |
| 2018-02-08 | B. Riley FBR | Buy | Initiate | |
| 2018-02-08 | B. Riley | Buy | Initiate | |
| 2017-12-04 | JP Morgan | Overweight | Initiate | |
| 2017-12-04 | Citigroup | Buy | Initiate | |
| 2023-02-21 | Stifel | Buy | Maintains | |
| 2023-02-21 | Baird | Outperform | Maintains | |
| 2023-02-21 | Citigroup | Buy | Maintains | |
| 2023-02-21 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-02-21 | Needham | Buy | Reiterate | |
| 2023-02-22 | Raymond James | Strong Buy | Maintains | |
| 2023-02-22 | Needham | Buy | Maintains | |
| 2023-02-23 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-01-03 | Wells Fargo | Overweight | Equal-Weight | Downgrade |
| 2023-05-08 | Citigroup | Buy | Maintains | |
| 2023-04-20 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-04-14 | Goldman Sachs | Buy | Maintains | |
| 2023-04-17 | Wedbush | Neutral | Maintains | |
| 2023-05-05 | Raymond James | Strong Buy | Maintains | |
| 2023-05-05 | Credit Suisse | Neutral | Maintains | |
| 2023-05-05 | Wells Fargo | Equal-Weight | Maintains | |
| 2023-05-05 | HC Wainwright & Co. | Buy | Maintains | |
| 2023-05-05 | Needham | Buy | Maintains | |
| 2023-05-12 | Oppenheimer | Outperform | Outperform | Maintains |
| 2023-06-13 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-09-08 | B of A Securities | Neutral | Neutral | Maintains |
| 2023-08-23 | Wedbush | Neutral | Neutral | Reiterate |
| 2023-08-23 | UBS | Buy | Buy | Maintains |
| 2023-08-23 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-08-29 | Stifel | Buy | Buy | Maintains |
| 2023-08-23 | Oppenheimer | Outperform | Outperform | Reiterate |
| 2023-12-05 | B of A Securities | Neutral | Buy | Upgrade |
| 2023-09-20 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-07-21 | Citigroup | Buy | Buy | Maintains |
| 2023-07-21 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2023-08-24 | Needham | Buy | Buy | Reiterate |
| 2024-02-16 | Mizuho | Neutral | Neutral | Maintains |
| 2023-11-09 | Goldman Sachs | Buy | Initiate | |
| 2023-10-12 | B of A Securities | Neutral | Neutral | Maintains |
| 2024-04-17 | Wedbush | Neutral | Neutral | Maintains |
| 2023-08-30 | Citigroup | Buy | Buy | Maintains |
| 2023-08-30 | Needham | Buy | Buy | Reiterate |
| 2023-07-31 | Needham | Buy | Buy | Maintains |
| 2023-07-31 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-07-20 | Wedbush | Neutral | Neutral | Maintains |
| 2023-07-20 | Wells Fargo | Equal-Weight | Equal-Weight | Maintains |
| 2023-07-20 | JP Morgan | Overweight | Overweight | Maintains |
| 2023-07-18 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-08-03 | JP Morgan | Overweight | Neutral | Downgrade |
| 2023-07-20 | Citigroup | Buy | Buy | Maintains |
| 2023-09-14 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-09-26 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-12-14 | Wells Fargo | Overweight | Equal-Weight | Downgrade |
| 2023-12-14 | Needham | Buy | Buy | Maintains |
| 2023-08-01 | Baird | Outperform | Outperform | Maintains |
| 2023-08-01 | B of A Securities | Buy | Neutral | Downgrade |
| 2023-08-01 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-08-01 | Raymond James | Strong Buy | Strong Buy | Maintains |
| 2024-04-29 | Mizuho | Neutral | Neutral | Maintains |
| 2024-03-27 | Mizuho | Neutral | Neutral | Maintains |
| 2023-08-07 | Wedbush | Neutral | Neutral | Maintains |
| 2023-08-07 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-09-15 | Wells Fargo | Equal-Weight | Overweight | Upgrade |
| 2023-10-06 | Citigroup | Buy | Buy | Maintains |
| 2023-10-06 | JP Morgan | Neutral | Overweight | Upgrade |
| 2023-10-06 | Raymond James | Strong Buy | Strong Buy | Maintains |
| 2024-01-24 | Needham | Buy | Buy | Maintains |
| 2023-11-02 | Raymond James | Strong Buy | Strong Buy | Maintains |
| 2023-11-02 | Mizuho | Neutral | Initiate | |
| 2023-11-01 | Needham | Buy | Buy | Maintains |
| 2024-04-09 | Needham | Buy | Buy | Reiterate |
| 2024-04-26 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-12-15 | Citigroup | Buy | Buy | Maintains |
| 2023-12-15 | Oppenheimer | Outperform | Outperform | Maintains |
| 2023-12-15 | Raymond James | Strong Buy | Strong Buy | Maintains |
| 2024-01-11 | Raymond James | Strong Buy | Strong Buy | Maintains |
| 2024-05-08 | UBS | Buy | Buy | Maintains |
| 2024-02-05 | Jefferies | Hold | Buy | Upgrade |
| 2024-03-06 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-05-23 | Wells Fargo | Equal-Weight | Equal-Weight | Maintains |
| 2024-01-30 | Oppenheimer | Outperform | Outperform | Maintains |
| 2024-05-28 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-04-15 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-01-09 | Goldman Sachs | Buy | Buy | Maintains |
| 2024-02-06 | Baird | Outperform | Outperform | Reiterate |
| 2024-01-12 | Wedbush | Neutral | Neutral | Maintains |
| 2024-05-31 | Piper Sandler | Neutral | Initiate | |
| 2024-03-04 | UBS | Buy | Buy | Maintains |
| 2024-02-28 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-02-28 | Wedbush | Neutral | Neutral | Maintains |
| 2024-04-25 | Needham | Buy | Buy | Reiterate |
| 2024-01-17 | Baird | Outperform | Outperform | Maintains |
| 2024-01-17 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-05-08 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-05-08 | Citigroup | Buy | Buy | Maintains |
| 2024-05-08 | Needham | Buy | Buy | Reiterate |
| 2024-06-28 | Baird | Outperform | Outperform | Maintains |
| 2024-07-26 | Baird | Outperform | Outperform | Maintains |
| 2024-09-13 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-08-09 | Wedbush | Neutral | Neutral | Maintains |
| 2024-08-09 | Goldman Sachs | Buy | Buy | Maintains |
| 2024-08-09 | Baird | Outperform | Outperform | Maintains |
| 2024-08-09 | Needham | Buy | Buy | Reiterate |
| 2025-04-02 | Scotiabank | Sector Perform | Sector Perform | Maintains |
| 2025-05-09 | Raymond James | Strong Buy | Outperform | Downgrade |
| 2025-05-09 | B of A Securities | Buy | Neutral | Downgrade |
| 2024-08-09 | UBS | Buy | Buy | Maintains |
| 2025-01-14 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-08-01 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2024-08-02 | Needham | Buy | Buy | Reiterate |
| 2024-10-16 | William Blair | Outperform | Initiate | |
| 2024-10-16 | Scotiabank | Sector Perform | Initiate | |
| 2025-08-01 | Citigroup | Buy | Buy | Maintains |
| 2024-07-17 | Goldman Sachs | Buy | Buy | Maintains |
| 2024-12-17 | Goldman Sachs | Buy | Neutral | Downgrade |
| 2024-11-07 | Baird | Outperform | Outperform | Maintains |
| 2024-08-02 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-08-02 | Goldman Sachs | Buy | Buy | Maintains |
| 2024-11-06 | Wells Fargo | Equal-Weight | Equal-Weight | Maintains |
| 2024-11-06 | Scotiabank | Sector Perform | Sector Perform | Maintains |
| 2024-11-06 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2024-11-06 | Goldman Sachs | Buy | Buy | Maintains |
| 2024-11-06 | Citigroup | Buy | Buy | Maintains |
| 2024-11-06 | Oppenheimer | Outperform | Outperform | Maintains |
| 2024-11-06 | Piper Sandler | Neutral | Neutral | Maintains |
| 2024-11-06 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-11-06 | B of A Securities | Buy | Buy | Maintains |
| 2024-11-06 | Needham | Buy | Buy | Maintains |
| 2024-09-20 | Needham | Buy | Buy | Reiterate |
| 2024-09-20 | Mizuho | Neutral | Neutral | Maintains |
| 2024-07-23 | Baird | Outperform | Outperform | Maintains |
| 2024-07-31 | Jefferies | Buy | Buy | Maintains |
| 2025-01-21 | RBC Capital | Sector Perform | Sector Perform | Reiterate |
| 2024-10-24 | Mizuho | Neutral | Neutral | Maintains |
| 2024-09-23 | Baird | Outperform | Outperform | Maintains |
| 2025-01-29 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2025-03-03 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-02-13 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-11-21 | Morgan Stanley | Equal-Weight | Initiate | |
| 2024-09-24 | Wells Fargo | Equal-Weight | Equal-Weight | Maintains |
| 2024-08-13 | JP Morgan | Overweight | Overweight | Maintains |
| 2025-03-03 | Goldman Sachs | Neutral | Neutral | Maintains |
| 2025-03-03 | Wedbush | Neutral | Neutral | Maintains |
| 2025-03-03 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2024-11-04 | RBC Capital | Sector Perform | Sector Perform | Reiterate |
| 2025-05-07 | Needham | Buy | Buy | Maintains |
| 2025-03-04 | JP Morgan | Overweight | Overweight | Maintains |
| 2025-07-02 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2025-07-18 | Baird | Outperform | Outperform | Maintains |
| 2025-04-21 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2025-05-22 | Citigroup | Buy | Buy | Maintains |
| 2025-05-14 | Mizuho | Neutral | Neutral | Maintains |
| 2025-06-02 | Wells Fargo | Equal-Weight | Equal-Weight | Maintains |
| 2025-04-29 | Cantor Fitzgerald | Overweight | Initiate | |
| 2025-05-08 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2025-05-08 | Scotiabank | Sector Perform | Sector Perform | Maintains |
| 2025-05-08 | Wells Fargo | Equal-Weight | Equal-Weight | Maintains |
| 2025-05-08 | Baird | Outperform | Outperform | Maintains |
| 2025-07-16 | B of A Securities | Neutral | Neutral | Maintains |
| 2025-08-01 | Cantor Fitzgerald | Overweight | Overweight | Maintains |
| 2025-08-01 | Raymond James | Outperform | Outperform | Maintains |
| 2025-07-29 | Citigroup | Buy | Buy | Maintains |
| 2025-08-04 | JP Morgan | Overweight | Overweight | Maintains |
